GSK stock: buy or sell?
January 17th, 2020
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide.
Should I buy GSK stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, 2 buy setups match with GlaxoSmithKline stock right now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is GlaxoSmithKline stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 15 ratings published for GSK stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-30||Jefferies Financial Group||n/a||Buy|
|2019-9-27||JPMorgan Chase & Co.||n/a||Neutral|
|2019-9-27||Goldman Sachs Group||n/a||Buy|
|2019-9-20||JPMorgan Chase & Co.||n/a||Neutral|
|2019-9-13||Bank of America||n/a||Neutral|
|2019-8-29||Jefferies Financial Group||n/a||Buy|
GSK stock analysis
After several days of continuous hikes in past weeks, GlaxoSmithKline raised 1.55% to $47.89.
Shares of GlaxoSmithKline closed yesterday at $47.89 after reaching a new all time high ($48.22) and raised a beatiful 1.55%. On September GSK price bounced up over the SMA of 50 days demonstrating to be a significant support for this stock.
GlaxoSmithKline closed this week at $47.89 after reaching a new all time high ($48.22) and jumped a fine 2.35%.
GSK shows a strong mid-term uptrend with several rising tops and rising bottoms. Since its last bottom last week, GSK climbed unceasignly breaking out to new all time highs. Since price and SMA40w lines crossed up early June, GSK climbed $10.12 (26.79%). By mid March 2019, SMA20w and SMA40w crossed up triggering a rise of 22.04%.
GSK stock price history
GSK IPO was on March 28th, 1980 at $0.00 per share1. Since then, GSK stock grew a inf%, with an average of inf% per year. If you had invested right after GSK's IPO a $1,000 in GSK stock in 1980, it would worth $inf today.
1: Adjusted price after possible price splits or reverse-splits.
GSK stock historical price chart
GSK stock reached all-time highs yesterday with a price of $48.22.
GSK stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' GSK stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price prediction for GlaxoSmithKline stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, GlaxoSmithKline presented its financial report, posting a great gain for the Earnings per Share (EPS) ratio. Experts were expecting $0.70 per share, but GlaxoSmithKline posted $0.79.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a tiny increase of 2.10% to $30,821.00 M dollars. When comparing 2018 vs 2017, in line, profit margin (that is, the net income divided by revenues) rose a 6.68% to 11.75%.
|2013||$26,510 M||-||$5,440 M20.5%||-|
|2014||$35,840 M||35.19%||$4,293 M12.0%||-21.08%|
|2015||$23,923 M||-33.25%||$8,422 M35.2%||96.16%|
|2016||$27,889 M||16.58%||$912 M3.3%||-89.17%|
|2017||$30,186 M||8.24%||$1,532 M5.1%||67.98%|
|2018||$30,821 M||2.10%||$3,623 M11.8%||136.49%|
Quarterly financial resultsGlaxoSmithKline reported $8,197.00 million in sales for 2018-Q4, a 1.30% improvement compared to previous quarter. Reported quarter earnings marked $1,215.00 million with a profit margin of 14.82%. Profit margin depreciated a -2.70% compared to previous quarter when profit margin was 17.52%. When comparing turnover to same quarter last year, GlaxoSmithKline sales marked a frightening loss and plunged a -20.59%. Looking back to recent quarterly results, GlaxoSmithKline posted 3 negative quarters in a row.
|2017-Q2||$7,320 M||-||$-180 M-2.5%||-|
|2017-Q3||$10,507 M||43.54%||$1,624 M15.5%||-1,002.02%|
|2017-Q4||$10,323 M||-1.75%||$-738 M-7.1%||-145.44%|
|2018-Q1||$7,222 M||-30.04%||$549 M7.6%||-174.41%|
|2018-Q2||$7,310 M||1.22%||$441 M6.0%||-19.67%|
|2018-Q3||$8,092 M||10.70%||$1,418 M17.5%||221.54%|
|2018-Q4||$8,197 M||1.30%||$1,215 M14.8%||-14.32%|
|2019-Q1||$7,661 M||-6.54%||$830 M10.8%||-31.69%|
GlaxoSmithKline ownershipWhen you are planning to buy a stock, it's always worth to overview its ownership structure.
GlaxoSmithKline shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.01% of all shares.
In case of GlaxoSmithKline stock, 11.66% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for GSK stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to GlaxoSmithKline:
|Market cap||$119.2 B|
|Total shares||2,490.0 M|
|Float shares||2,450.0 M|
|- Institutional holdings (%)||11.7%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, January 17th, 2020|
|Day range||$47.80 - $48.22|
|Average true range||$0.48|
|50d mov avg||$45.74|
|100d mov avg||$43.82|
|200d mov avg||$41.61|
GlaxoSmithKline performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared GlaxoSmithKline against in the following table:
GlaxoSmithKline competitorsUnfortunately, we could not find any public company that could be defined as GlaxoSmithKline competitor. This doesn't mean GlaxoSmithKline does not have any competitor in the market, it's just we could not detected it.
Latest GSK stock news
- Seeking AlphaGlaxoSmithKline Looks To Boost Sales Of Zejula Upon Potential FDA Approval In Another IndicationJuly 31, 2019
- Seeking AlphaGlaxoSmithKline And Linerixibat In Cholestasis Pruritus: It Is Worth A LookJuly 3, 2019
- Seeking AlphaWe May Pick Up GlaxoSmithKline At Cheaper PricesJune 10, 2019
- Seeking AlphaGlaxoSmithKline & AstraZeneca, Two Brexit Cancellation Income PlaysApril 29, 2019
- Seeking AlphaGlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-OncologyFebruary 11, 2019